This research study is evaluating to examine the efficacy of a novel a self-administered digital application (DREAMLAND) for improving patients' long-term quality of life and psychological outcomes for patients with acute myeloid leukemia undergoing intensive chemotherapy.
Hospitalized patients (age > 18 years) with a diagnosis of AML.
Initiating treatment with either a) intensive chemotherapy (7+3) or modification of this regimen on a clinical trial, or a similar intensive regimen or b) hypomethylating agents (HMA) +/- additional agents or modification of this regimen on a clinical trial.
Ability to comprehend and speak English as the digital apps are only available in English
Patients with a diagnosis of acute promyelocytic leukemia
Patients with acute or unstable psychiatric or cognitive conditions which the treating clinicians believes prohibits informed consent or compliance with study procedures.
Massachusetts General Hospital
Lead sponsor
National Cancer Institute (NCI)
Collaborator